LDN - Studie bei der UCSF .. (Forum)

TOM ⌂, 93197 Zeitlarn/Regendorf, Donnerstag, 28. Juni 2007, 13:21 (vor 3892 Tagen)

Hi allerseits,

gerade habe ich bei "www.acceleratedcure.org" (USA) folgendes gelesen:

<i>"This study is taking place at UCSF (in San Francisco):

Low Dose Naltrexone
A Randomized, Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone on Quality of Life as Measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI54)

Dr. Bruce Cree and his colleagues from the UCSF department of Neurology are running this randomized, double-masked, placebo-control, cross-over clinical trial to evaluate the efficacy of Low Dose Naltrexone (LDN) on the quality of life of MS patients.

Naltrexone has been approved by the U.S. Food and Drug Administration (FDA) to treat alcohol and opioid addictions (using 50 mg dosages). Whether LDN has any benefit for people with MS is currently unknown.

LDN may assist you with your MS in one of two ways:

* By improving your immune system’s function through increasing the level of endorphins and enkephalins, chemicals which are produced by your nervous and immune systems.
* By reducing the activity of cells that damage the brain and spinal cord in MS.

If you participate, you will be randomly assigned to one of two groups. Both groups will receive LDN for eight weeks and a placebo for eight weeks. One of the groups will receive the LDN first, and the other group will receive it last. Neither you nor your doctor will know which group you are in until after the study is complete.

If you enroll in this study, you must continue to take any MS medications that you’re already taking. For eight weeks, you will take either the LDN or the inactive placebo every night before going to bed between the hours of 9:00 PM to 3:00 AM. You will take neither drug for the ninth week. Finally, you will take the other drug for the last eight weeks of the trial. You will be asked to answer a questionnaire (called “MSQLI54”) at the baseline and at weeks 8 and 17.

Additional treatment with LDN is not offered as part of this study, but once the study is completed, you will be notified if a beneficial effect of LDN has been found. If the study finds that LDN is beneficial, you can discuss off-label treatment with LDN with your doctor. LDN is available through some compounding pharmacies.

To request additional information, phone (415) 514-3815. " </i>

... hört sich gut an ..mal sehen, was dabei herauskommt ...

So long

TOM


Re: LDN - Studie bei der UCSF ..

grischan, Dienstag, 03. Juli 2007, 16:10 (vor 3887 Tagen) @ TOM


Als Antwort auf: LDN - Studie bei der UCSF .. von TOM am 28. Juni 2007 13:21:46:


Klingt wirklich gut. Nur leider wieder etwas kurz, um die Wirkung zu sehen...

Aber besser als nix;-))

Grüße,
grischan

RSS-Feed dieser Diskussion
powered by my little forum